HK Stock MarketDetailed Quotes
01099 SINOPHARM
- 19.940
- -0.460-2.25%
Not Open Jan 20 16:08 CST
62.23BMarket Cap6.81P/E (TTM)
20.600High19.940Low6.33MVolume20.400Open20.400Pre Close127.49MTurnover0.47%Turnover Ratio6.23P/E (Static)3.12BShares23.65052wk High0.73P/B26.76BFloat Cap16.02052wk Low0.96Dividend TTM1.34BShs Float40.024Historical High0.956Dividend LFY3.24%Amplitude8.756Historical Low20.128Avg Price400Lot Size4.79%Div YieldTTM4.79%Div Yield LFY
SINOPHARM Stock Forum
Sign in to post a comment
US Market Key Charts (S&P, US Dollar, Gold)
$E-mini S&P 500 Futures(MAR5) (ESmain.US)$(4 Hour Chart) -[BULLISH↗ *]We stay slightly bullish as we expect price to push towards 6000 resistance level. A 4 hour candlestick closing above 6000 resistance level would open a push towards 6035 resistance level. Technical indicators have yet to indicate a bullish scenario.
Alternatively: A 4 hour candlesti...
$E-mini S&P 500 Futures(MAR5) (ESmain.US)$(4 Hour Chart) -[BULLISH↗ *]We stay slightly bullish as we expect price to push towards 6000 resistance level. A 4 hour candlestick closing above 6000 resistance level would open a push towards 6035 resistance level. Technical indicators have yet to indicate a bullish scenario.
Alternatively: A 4 hour candlesti...
25
2
1
Analysts have downgraded their earnings per share estimates for Sinopharm Group, indicating a decline in sentiment. They also suggest that Sinopharm may underperform compared to the wider industry, but the consensus price target remains steady.
2
Sinopharm Group's declining ROCE trend is concerning. Increased capital investment without matching sales suggests long-term plays. High current liabilities to total assets ratio introduces risk. These trends indicate Sinopharm may not be a multi-bagger.
1
$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...
1
1
Sinopharm Group's low P/E ratio is due to investors' limited growth expectations, leading to a reduced stock price. The poor earnings outlook from analysts also contributes to its low P/E. These conditions may continue to hinder the share price.
Sinopharm Group is currently undervalued and it might be a good time to accumulate more holdings in the stock. The positive outlook on the horizon of the company's future seems not to be fully factored into the current share price.
1
The declining trend in Sinopharm Group's ROCE and the stock's 42% fall in the last five years doesn't inspire investor confidence. The article doesn't consider Sinopharm Group as a potential multi-bagger based on the present analysis.
$SINOPHARM (01099.HK)$
Sinopharm is principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is en...
Sinopharm is principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is en...
3
https://alphaedgeinvesting.com/2022/08/30/dbs-china-healthcare-sector-pharmaceutical-packaging/
$MICROPORT (00853.HK)$ $WEIGAO GROUP (01066.HK)$ $CSPC PHARMA (01093.HK)$ $SINOPHARM (01099.HK)$ $CR MEDICAL (01515.HK)$ $CONSUN PHARMA (01681.HK)$ $CHUNLI MEDICAL (01858.HK)$ $UNI MEDICAL (02666.HK)$ $HENLIUS (02696.HK)$ $B-Soft Co.,Ltd. (300451.SZ)$ $Guangxi LiuYao Group (603368.SH)$ $BEIGENE (06160.HK)$
$MICROPORT (00853.HK)$ $WEIGAO GROUP (01066.HK)$ $CSPC PHARMA (01093.HK)$ $SINOPHARM (01099.HK)$ $CR MEDICAL (01515.HK)$ $CONSUN PHARMA (01681.HK)$ $CHUNLI MEDICAL (01858.HK)$ $UNI MEDICAL (02666.HK)$ $HENLIUS (02696.HK)$ $B-Soft Co.,Ltd. (300451.SZ)$ $Guangxi LiuYao Group (603368.SH)$ $BEIGENE (06160.HK)$
No comment yet
Heat List
HK
Overall
Symbol
Price
% Chg
No Data
Cui Nyonya Kueh :
Musang Siguntang : ???